Immuneering (NASDAQ:IMRX) Stock Rating Upgraded by Chardan Capital

Immuneering (NASDAQ:IMRX) was upgraded by investment analysts at Chardan Capital to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research firms also recently weighed in on IMRX. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Wednesday, June 24th. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Needham & Company LLC lifted their target price on Immuneering from $11.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. Cantor Fitzgerald assumed coverage on shares of Immuneering in a research report on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price target on the stock. Finally, Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $18.00.

Immuneering Trading Down 0.2%

IMRX stock opened at $4.39 on Monday. Immuneering has a twelve month low of $2.90 and a twelve month high of $10.08. The company has a market capitalization of $284.03 million, a P/E ratio of -3.75 and a beta of 0.43. The firm has a 50 day simple moving average of $4.60 and a 200-day simple moving average of $4.98.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). The company had revenue of $0.36 million for the quarter. On average, research analysts predict that Immuneering will post -1.09 EPS for the current year.

Hedge Funds Weigh In On Immuneering

Several institutional investors have recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Immuneering in the 1st quarter worth about $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Immuneering during the 4th quarter valued at about $33,000. Levin Capital Strategies L.P. acquired a new stake in shares of Immuneering in the first quarter valued at approximately $53,000. Focus Financial Network Inc. acquired a new position in shares of Immuneering during the second quarter worth approximately $62,000. Finally, Cetera Investment Advisers bought a new position in Immuneering in the 1st quarter worth approximately $67,000. Institutional investors own 67.65% of the company’s stock.

Key Immuneering News

Here are the key news stories impacting Immuneering this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy” rating and a $14 price target, implying substantial upside from the reference price of $4.39. HC Wainwright starts Immuneering at Buy
• Positive Sentiment: Chardan Capital upgraded Immuneering to “Strong Buy,” adding to the favorable analyst sentiment around IMRX.
• Positive Sentiment: Immuneering reported a 17.3-month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib plus chemotherapy. The company said 84% of evaluable patients were weight-stable or gained weight after three months, supporting the drug’s potential efficacy and tolerability. Immuneering second-quarter financial results and business updates
• Positive Sentiment: The pivotal Phase 3 MAPKeeper 301 trial is enrolling and dosing patients across more than 30 locations. Management expects the company’s $182.7 million cash position to fund operations into 2029, reducing near-term financing pressure.
• Positive Sentiment: A peer-reviewed Cancer Research publication highlighted atebimetinib’s broad preclinical activity against RAS- and RAF-mutant tumors and potential for favorable tolerability.
• Neutral Sentiment: Upcoming catalysts include an expected Phase 2 atebimetinib and anti-PD-1 lung cancer study initiation in the second half of 2026, additional preclinical data in the fourth quarter, and MAPKeeper 301 topline results targeted for mid-2028.
• Negative Sentiment: Second-quarter adjusted results were slightly weaker than expected: Immuneering reported a $0.27 per-share loss versus the $0.26 consensus loss, while revenue was only $0.36 million.
• Negative Sentiment: The quarterly net loss widened to $17.3 million from $14.4 million a year earlier, with research and development costs rising to $14.0 million as clinical spending increased. IMRX remains unprofitable and has not yet completed a registrational trial.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.